FEATURED ARTICLES
Milken Institute's Kristin Schneeman explains how a new action plan could broaden patient access in the U.S. — and what sponsors and policymakers can do now.
-
Testing Early Treatment In Head And Neck Cancer Without Compromising Curative Care
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.
-
Can Psychedelic‑Assisted Treatment Redefine Emotional Care In Oncology?
Psychedelic-assisted treatment may offer faster, lasting relief for cancer patients facing adjustment disorder, depression, and anxiety.
-
Can A Universal Health Screening Help Stop Clinical Trial Dropouts?
Could comprehensive health scans give trial participants meaningful value — and help sponsors reduce costly dropouts?